149 related articles for article (PubMed ID: 36714975)
21. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
Lang FF; Miller DC; Koslow M; Newcomb EW
J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
[TBL] [Abstract][Full Text] [Related]
22. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas.
Newcomb EW; Alonso M; Sung T; Miller DC
Hum Pathol; 2000 Jan; 31(1):115-9. PubMed ID: 10665922
[TBL] [Abstract][Full Text] [Related]
23. Metallothionein Genes are Highly Expressed in Malignant Astrocytomas and Associated with Patient Survival.
Masiulionytė B; Valiulytė I; Tamašauskas A; Skiriutė D
Sci Rep; 2019 Apr; 9(1):5406. PubMed ID: 30932010
[TBL] [Abstract][Full Text] [Related]
24. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
25. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
[TBL] [Abstract][Full Text] [Related]
26. Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma.
Tanizaki Y; Sato Y; Oka H; Utsuki S; Kondo K; Miyajima Y; Nagashio R; Fujii K
Pathol Int; 2006 Sep; 56(9):510-5. PubMed ID: 16930331
[TBL] [Abstract][Full Text] [Related]
27. ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas.
Tomaselli S; Galeano F; Massimi L; Di Rocco C; Lauriola L; Mastronuzzi A; Locatelli F; Gallo A
BMC Cancer; 2013 May; 13():255. PubMed ID: 23697632
[TBL] [Abstract][Full Text] [Related]
28. Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers.
Ichimura K; Narita Y; Hawkins CE
Acta Neuropathol; 2015 Jun; 129(6):789-808. PubMed ID: 25975377
[TBL] [Abstract][Full Text] [Related]
29. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
Ohgaki H; Kleihues P
J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
[TBL] [Abstract][Full Text] [Related]
30. Timing of p53 mutations during astrocytoma tumorigenesis.
del Arco A; García J; Arribas C; Barrio R; Blázquez MG; Izquierdo JM; Izquierdo M
Hum Mol Genet; 1993 Oct; 2(10):1687-90. PubMed ID: 8268922
[TBL] [Abstract][Full Text] [Related]
31. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
Pollack IF; Finkelstein SD; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Finlay JL; Sposto R;
Cancer Res; 2001 Oct; 61(20):7404-7. PubMed ID: 11606370
[TBL] [Abstract][Full Text] [Related]
32. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults.
Matsumoto T; Fujii T; Yabe M; Oka K; Hoshi T; Sato K
Histopathology; 1998 Nov; 33(5):446-52. PubMed ID: 9839169
[TBL] [Abstract][Full Text] [Related]
33. TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas.
Rorive S; Lopez XM; Maris C; Trepant AL; Sauvage S; Sadeghi N; Roland I; Decaestecker C; Salmon I
Mod Pathol; 2010 Oct; 23(10):1418-28. PubMed ID: 20693981
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors.
Rathore A; Kamarajan P; Mathur M; Sinha S; Sarkar C
Pathol Oncol Res; 1999; 5(1):21-7. PubMed ID: 10079373
[TBL] [Abstract][Full Text] [Related]
35. Activation of EGFR signaling from pilocytic astrocytomas to glioblastomas.
Carvalho PO; Uno M; Oba-Shinjo SM; Rosemberg S; Wakamatsu A; da Silva CC; Teixeira MJ; Marie SK
Int J Biol Markers; 2014 Jun; 29(2):e120-8. PubMed ID: 24170555
[TBL] [Abstract][Full Text] [Related]
36. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N
Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
[TBL] [Abstract][Full Text] [Related]
38. Expression patterns of Wnt signaling component, secreted frizzled‑related protein 3 in astrocytoma and glioblastoma.
Pećina-Šlaus N; Kafka A; Varošanec AM; Marković L; Krsnik Ž; Njirić N; Mrak G
Mol Med Rep; 2016 May; 13(5):4245-51. PubMed ID: 27035837
[TBL] [Abstract][Full Text] [Related]
39. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
Mott RT; Turner KC; Bigner DD; McLendon RE
J Neurosurg; 2008 Feb; 108(2):330-5. PubMed ID: 18240930
[TBL] [Abstract][Full Text] [Related]
40. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.
Ramachandran RK; Sørensen MD; Aaberg-Jessen C; Hermansen SK; Kristensen BW
PLoS One; 2017; 12(2):e0172234. PubMed ID: 28234925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
